Impact of statin pretreatment on the complications of carotid stenting in asymptomatic patients: observational study

BMC Neurology

Huimahn Choi¹  Seong Hwa Jang²  Jeong-Ho Hong²  Doo Hyuk Kwon²  Sung-Il Sohn²  Hyungjong Park²  Moon-Ku Han³ 

[1] Department of Neurology and Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston;Department of Neurology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine;Department of Neurology, Seoul National University Bundang Hospital, Seoul National University School of Medicine;

关键词: Carotid stenosis;    Stents;    Complications;    Statin;   

DOI  :  10.1186/s12883-021-02104-z

来源: DOAJ

【 摘 要 】

Abstract Background Carotid stenosis is a known risk factor for ischemic stroke, and carotid artery stenting is an effective preventive procedure. However, the stroke risk reduction for asymptomatic patients is small. Therefore, it is important to reduce the risk of complications, particularly in asymptomatic carotid stenosis. Statins are known to reduce the overall risk of periprocedural complications, although there is a lack of data focusing on asymptomatic patients. We aimed to investigate whether different doses of statin pretreatment can reduce periprocedural complications of carotid artery stenting (CAS) in patients with asymptomatic carotid artery stenosis. Methods Between July 2003 and June 2013, 276 consecutive patients received CAS for asymptomatic carotid stenosis. Periprocedural complications included the outcome of stroke, myocardial infarction, or death within 30 days of CAS. Statin pretreatment was categorized as no-statin (n = 87, 31.5%), standard-dose (< 40 mg, n = 139, 50.4%), and high-dose statin (≥40 mg, n = 50, 18.1%) according to the atorvastatin equivalent dose. The Cochran-Armitage (CA) trend test was performed to investigate the association of periprocedural complications with statin dose. Results The overall periprocedural complication rate was 3.3%. There was no significant difference in the risk of periprocedural complications between the three groups (no statin: n = 3 [3.4%]; standard-dose: n = 4 [2.9%]; high-dose n = 2 [4.0%] p = 0.923). The CA trend test did not demonstrate a trend in the proportion of periprocedural complications across increasing statin equivalent doses (p = 0.919). Conclusions Statin pretreatment before CAS showed neither absolute nor dose-dependent effects against periprocedural complications in asymptomatic patients undergoing CAS.

【 授权许可】

Unknown